Modus Therapeutics is a Swedish drug development company developing sevuparin – a new drug to treat people suffering from Sickle Cell Disease (SCD) – a painful, inherited blood disorder affecting millions of people around the globe.
Sickle Cell Disease patients’ blood cells form a sickled shape, which makes blood flow to vital organs difficult, causing severe pain and even premature death. Sevuparin has the potential to improve the SCD patients’ blood flow by reducing their pain and the amount of time they will need to spend in hospital. Modus Therapeutics plans to develop a formulation of sevuparin that the patient can self-administer allowing them to live a more normal life by preventing the painful episodes requiring hospital care.
Modus Therapeutics is predominantly owned by KDev Investments AB, part of Karolinska Development AB (Nasdaq Stockholm: KDEV) and Rosetta Capital. Other larger owners are HealthCap, The Foundation for Baltic and European Studies (Östersjöstiftelsen), Ergomed and Praktikerinvest PE AB.